No evidence of benefit with vitamin d supplementation in indolent lymphoma, and important question addressed by Jonathan Friedberg Wilmot Cancer Institute #ASH2023

BV with DTIC or nivo induction in older patients with HL: long follow-up demonstrates some likely cures. Blood Journal ashpublications.org/blood/article-…

#ASH23 Jonathan Friedberg et al Ilyad study: RCT of vitamin D supplementation vs placebo in low tumor burden indolent lymphoma treated with rituximab mono therapy
- n=206
- no diff in ORR, EFS
- long awaited, great question, shame about the answer
#lymSM
ash.confex.com/ash/2023/webpr…

Mapping the metrics #WiL improve the metrics!
Today Women In Lymphoma - [email protected] co-authors Eliza Hawkes Carla Casulo, MD Soni Smith MD Ann LaCasce, MD chart the low rate, 31% (3-50%) of female authors of lymphoma reviews & editorials in the leading medical journals.
thelancet.com/journals/lance…

Career development: A balance of opportunities and choices
onlinelibrary.wiley.com/doi/10.1002/ho… A wonderful perspective from three legendary #WiL Lena Specht, Daphne de Jong and Eva Kimby!

So many #changechampions International Conference on Malignant Lymphoma committed to productive diversity in #lymphoma care, teaching and research. Such a positive way to start #ICML23 in a room of lymphoma giants! #lymsm

I continue to be so amazingly grateful to the amazing #WoMMen in #MMsm who’ve mentored me so much (Nina Shah Sandy Wong and many more!)

Kudos Women In Lymphoma - [email protected] Eddie Cliff - we need more of these #Heforshe initiatives across malignant hematology!

This is a must read! This quote from the editorial makes me really sad & disappointed as it alludes to the main reason of why we now have two competing classifications: 'In 2017, new leadership responsible for producing the WHO Classification of Tumors ascopubs.org/doi/full/10.12……

Amazing week with LRF LSRMP at Lake Las Vegas. Great protocol development. Meeting mentors and colleagues was invaluable! Lymphoma Research Foundation OSU Hematology

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma ashpublications.org/blood/article-…

Glad to see ODAC strongly support Pola-R-CHP for patients with newly diagnosed DLBCL with vote of 11-2. Eager for FDA approval soon.
cancerletter.com/regulatory-new…

Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter? Dr Kahl outlines a strategy which can serve as a template for incorporating novel agents into frontline management. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Thrilled to lead initiatives in this incredible group of #lymphoma experts! Looking forward to expanding our reach Women In Lymphoma - [email protected]!

So pleased to meet Dr Perez-Stable from NIH visiting UR Medicine!

Incredibly educational and a critical addition to the literature Blood Journal:
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee ashpublications.org/blood/article-…

So incredibly tragic and sad. I remember Dr. Heaney very fondly, the first to interview me at MSKCC for fellowship. Always encouraging and kind

Just completed my virtual 5K run for Wilmot Cancer Institute #WarrioWalk !

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial onlinelibrary.wiley.com/doi/10.1002/cn…

Treatment Outcomes in Patients Mantle Cell Lymphoma: These data support the ongoing ECOG-ACRIN Cancer Research Group trial evaluating the role of ASCT in patients achieving undetectable MRD after induction. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Follicular lymphoma: life beyond the third line thelancet.com/journals/lanha… Thank you Dr Silvia Montoto for your insightful commentary on our #FL paper The Lancet Haematology